NSCLC patients harboring EGFR activating mutations have been reported to be related to an increased response to platinum‐based chemotherapies as compared with EGFR wild‐type patients.17 Some studies have indicated that EGFR activating mutations may correlate with DNA damage repair deficiency.18 Different from wild‐type EGFR regulation on ERCC1 expression, in our study, we found EGFR exon 19 deletion signals could aberrantly downregulate ERCC1 expression. Here, ERCC1 is linked to non-small cell lung carcinoma.